Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

These days, many devices are programmed through apps on patients’ phones. But the FDA warns that certain phone settings, such ...

Managing diabetes is even harder when temperatures and humidity are rising. Find out how extreme heat can negatively affect ...

Fourteen-day continuous glucose monitoring (CGM) traces added to Diabetes Control and Complications Trial (DCCT) data can predict microvascular diabetes complications similarly to glycated hemoglobin.

Shanghai's Ruijin Hospital announced today that researchers have developed a groundbreaking non-invasive blood glucose ...

While prediabetes carries an increased risk of developing type 2 diabetes, Diabetes UK emphasizes that it can be reversed ...

The US Food and Drug Administration (FDA) is cautioning patients and caregivers about the potential for not receiving blood ...

Shanghai researchers have devised a revolutionary, non-invasive method to monitor blood glucose, allowing for accurate blood ...

The FDA today issued an alert around a safety concern regarding diabetes devices that rely on smartphones to deliver critical safety alerts.

In this free webinar, learn strategies for leveraging innovative endpoint solutions to enhance the safety, efficacy and patient-focused value of GLP-1 clinical trials. The featured speakers will ...

Glucose monitoring has evolved beyond its traditional role in diabetes management, with an increasing number of people using ...

Medical device specialist DexCom (NASDAQ: DXCM) has substantially underperformed the market over the trailing-12-month period ...